0.8632
price down icon5.14%   -0.0468
after-market 시간 외 거래: .87 0.0068 +0.79%
loading
전일 마감가:
$0.91
열려 있는:
$0.94
하루 거래량:
1.79M
Relative Volume:
2.27
시가총액:
$68.66M
수익:
$101.21M
순이익/손실:
$-569.00K
주가수익비율:
-1.0276
EPS:
-0.84
순현금흐름:
$-56.88M
1주 성능:
-17.00%
1개월 성능:
-26.85%
6개월 성능:
-54.33%
1년 성능:
-34.61%
1일 변동 폭
Value
$0.8405
$0.94
1주일 범위
Value
$0.8405
$1.075
52주 변동 폭
Value
$0.8405
$5.85

Cytomx Therapeutics Inc Stock (CTMX) Company Profile

Name
명칭
Cytomx Therapeutics Inc
Name
전화
650.515.3185
Name
주소
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Name
직원
122
Name
트위터
@cytomxinc
Name
다음 수익 날짜
2024-11-07
Name
최신 SEC 제출 서류
Name
CTMX's Discussions on Twitter

CTMX을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
CTMX 0.8632 68.66M 101.21M -569.00K -56.88M -0.84
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-05-28 업그레이드 Piper Sandler Neutral → Overweight
2024-05-09 업그레이드 Wedbush Neutral → Outperform
2024-05-06 업그레이드 Jefferies Hold → Buy
2024-04-22 업그레이드 JP Morgan Underweight → Neutral
2022-11-14 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-07-07 다운그레이드 Jefferies Buy → Hold
2022-07-07 다운그레이드 Mizuho Buy → Neutral
2022-07-07 다운그레이드 Piper Sandler Overweight → Neutral
2022-07-07 다운그레이드 Wedbush Outperform → Neutral
2022-06-24 개시 BMO Capital Markets Outperform
2022-01-18 업그레이드 Barclays Underweight → Overweight
2021-11-15 개시 BTIG Research Buy
2021-05-28 다운그레이드 Barclays Equal Weight → Underweight
2021-03-29 개시 JP Morgan Overweight
2021-03-23 업그레이드 Jefferies Hold → Buy
2020-09-22 다운그레이드 Guggenheim Buy → Neutral
2020-06-01 다운그레이드 Jefferies Buy → Hold
2020-05-14 재확인 H.C. Wainwright Buy
2020-03-24 업그레이드 Wedbush Neutral → Outperform
2020-03-04 개시 Barclays Equal Weight
2019-11-20 개시 Guggenheim Buy
2019-11-11 다운그레이드 Wedbush Outperform → Neutral
2019-06-13 개시 Mizuho Buy
2019-05-14 개시 Cantor Fitzgerald Overweight
2019-03-11 개시 Barclays Overweight
2018-11-26 개시 Piper Jaffray Overweight
2018-10-15 개시 Goldman Neutral
2018-09-13 개시 H.C. Wainwright Buy
2018-06-01 개시 SunTrust Buy
2018-01-05 개시 Citigroup Buy
2017-09-08 개시 Wedbush Outperform
2017-03-27 개시 H.C. Wainwright Buy
2017-03-02 개시 Instinet Buy
2017-01-03 다운그레이드 Oppenheimer Outperform → Perform
2015-11-02 개시 Oppenheimer Outperform
모두보기

Cytomx Therapeutics Inc 주식(CTMX)의 최신 뉴스

pulisher
Nov 15, 2024

CytomX stock touches 52-week low at $0.98 amid market challenges - Investing.com Canada

Nov 15, 2024
pulisher
Nov 15, 2024

TANG CAPITAL MANAGEMENT LLC Acquires Shares in CytomX Therapeuti - GuruFocus.com

Nov 15, 2024
pulisher
Nov 14, 2024

Analysis of JANUS HENDERSON GROUP PLC's Recent Transaction in Cy - GuruFocus.com

Nov 14, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Bullish Estimate for CTMX FY2024 Earnings - Defense World

Nov 14, 2024
pulisher
Nov 13, 2024

HC Wainwright Has Positive Outlook for CTMX FY2024 Earnings - MarketBeat

Nov 13, 2024
pulisher
Nov 12, 2024

CytomX Therapeutics' SWOT analysis: biotech stock's potential in cancer treatment - Investing.com UK

Nov 12, 2024
pulisher
Nov 11, 2024

CytomX Therapeutics (NASDAQ:CTMX) Earns "Neutral" Rating from HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 09, 2024
pulisher
Nov 09, 2024

CytomX Therapeutics (NASDAQ:CTMX) Stock Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat

Nov 09, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc earnings beat by $0.24, revenue topped estimates - Investing.com Australia

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics (CTMX) Q3 Earnings and Revenues Top Estimates - MSN

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics: Q3 Earnings Snapshot - Darien Times

Nov 08, 2024
pulisher
Nov 08, 2024

CytomX Therapeutics Reports Q3 Progress and Growth - TipRanks

Nov 08, 2024
pulisher
Nov 07, 2024

CytomX stock touches 52-week low at $0.98 amid market shifts - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

CytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times

Nov 07, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 202 - GuruFocus.com

Nov 06, 2024
pulisher
Nov 06, 2024

Earnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 Result - Yahoo Finance

Nov 06, 2024
pulisher
Nov 03, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) Price Target at $5.77 - Defense World

Nov 03, 2024
pulisher
Nov 01, 2024

CytomX Therapeutics (CTMX) Set to Announce Earnings on Thursday - MarketBeat

Nov 01, 2024
pulisher
Oct 31, 2024

CytomX Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024 - The Manila Times

Oct 31, 2024
pulisher
Oct 31, 2024

Analysts Set CytomX Therapeutics, Inc. (NASDAQ:CTMX) PT at $5.77 - MarketBeat

Oct 31, 2024
pulisher
Oct 26, 2024

Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues - Simply Wall St

Oct 26, 2024
pulisher
Oct 25, 2024

CytomX stock plunges to 52-week low at $1.03 amid market challenges - Investing.com India

Oct 25, 2024
pulisher
Oct 17, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in September - MarketBeat

Oct 17, 2024
pulisher
Oct 15, 2024

CytomX Therapeutics Inc (CTMX) rating upgrades by Piper Sandler - Knox Daily

Oct 15, 2024
pulisher
Oct 15, 2024

Trading Day Triumph: CytomX Therapeutics Inc (CTMX) Ends at 1.09, a -5.22 Surge/Plunge - The Dwinnex

Oct 15, 2024
pulisher
Oct 15, 2024

CTMX Stock: A Comprehensive Analysis and Forecast - The InvestChronicle

Oct 15, 2024
pulisher
Oct 14, 2024

CytomX Therapeutics (NASDAQ:CTMX) & Immuneering (NASDAQ:IMRX) Head to Head Comparison - Defense World

Oct 14, 2024
pulisher
Oct 13, 2024

Squarepoint Ops LLC Has $243,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Oct 13, 2024
pulisher
Oct 11, 2024

Selling Buzz: CytomX Therapeutics Inc [CTMX] Chief Business Officer Landau Jeffrey B sells 4,181 shares of the company – Knox Daily - Knox Daily

Oct 11, 2024
pulisher
Oct 06, 2024

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 06, 2024
pulisher
Sep 30, 2024

There is no way CytomX Therapeutics Inc (CTMX) can keep these numbers up - SETE News

Sep 30, 2024
pulisher
Sep 29, 2024

Forefront Analytics LLC Has $78,000 Stock Position in CytomX Therapeutics, Inc. (NASDAQ:CTMX) - Defense World

Sep 29, 2024
pulisher
Sep 27, 2024

Wall Street SWOT: CytomX Therapeutics stock shows promise amid clinical trials - Investing.com

Sep 27, 2024
pulisher
Sep 27, 2024

CytomX Therapeutics Inc [NASDAQ: CTMX] Sees Increase in Stock Value - Knox Daily

Sep 27, 2024
pulisher
Sep 26, 2024

Investors in cash trouble should check out CytomX Therapeutics Inc (CTMX) - SETE News

Sep 26, 2024
pulisher
Sep 25, 2024

Is it possible to buy CytomX Therapeutics Inc(CTMX) shares at a good price now? - US Post News

Sep 25, 2024
pulisher
Sep 25, 2024

Metastatic Cancer Drugs Market Outlook, Insights, and Size: 2024-2033 - WhaTech

Sep 25, 2024
pulisher
Sep 24, 2024

CTMX stock rated an Overweight by Piper Sandler - Knox Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Investor’s Toolkit: Key Ratios for Assessing CytomX Therapeutics Inc (CTMX)’s Performance - The Dwinnex

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Reports Narrowed Losses - TipRanks

Sep 24, 2024
pulisher
Sep 24, 2024

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - StockTitan

Sep 24, 2024
pulisher
Sep 24, 2024

This trade activity should not be overlooked: Cytokinetics Inc (CYTK) - SETE News

Sep 24, 2024
pulisher
Sep 24, 2024

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Sep 24, 2024
pulisher
Sep 23, 2024

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN

Sep 23, 2024
pulisher
Sep 22, 2024

XTX Topco Ltd Makes New $889,000 Investment in Churchill Downs Incorporated (NASDAQ:CHDN) - MarketBeat

Sep 22, 2024
pulisher
Sep 21, 2024

Renaissance Technologies LLC Takes Position in ChampionX Co. (NASDAQ:CHX) - MarketBeat

Sep 21, 2024
pulisher
Sep 21, 2024

Tucows Inc. (NASDAQ:TCX) CEO Elliot Noss Sells 5,700 Shares of Stock - Defense World

Sep 21, 2024

Cytomx Therapeutics Inc (CTMX) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Cytomx Therapeutics Inc 주식 (CTMX) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Landau Jeffrey B
Chief Business Officer
Aug 20 '24
Sale
1.23
4,181
5,139
119,056
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Option Exercise
0.00
11,250
0
179,829
BELVIN MARCIA
SVP, Chief Scientific Officer
Aug 20 '24
Sale
1.23
4,181
5,139
175,648
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Option Exercise
0.00
11,250
0
134,978
ROWLAND LLOYD A
General Counsel
Aug 20 '24
Sale
1.23
4,181
5,139
130,797
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Option Exercise
0.00
6,875
0
110,061
Ogden Christopher
Chief Financial Officer
Aug 20 '24
Sale
1.23
1,984
2,439
108,077
McCarthy Sean A.
CEO
Aug 20 '24
Option Exercise
0.00
37,500
0
671,749
McCarthy Sean A.
CEO
Aug 20 '24
Sale
1.23
13,898
17,082
657,851
McCarthy Sean A.
CEO
Mar 26 '24
Option Exercise
1.57
109,768
172,874
634,249
$18.98
price up icon 3.66%
$76.97
price up icon 1.45%
$39.51
price up icon 7.22%
$359.21
price down icon 1.11%
$187.69
price down icon 0.81%
$101.87
price up icon 2.16%
자본화:     |  볼륨(24시간):